We are live on ! Find out more
AMPH icon

Amphastar Pharmaceuticals
AMPH

134 hedge funds and large institutions have $478M invested in Amphastar Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 47 increasing their positions, 50 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 15

3.57% more ownership

Funds ownership: 47.43% → 51% (+3.6%)

1% more capital invested

Capital invested by funds: $471M → $478M (+$6.53M)

1% more funds holding

Funds holding: 133 → 134 (+1)

6% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 50

96% less call options, than puts

Call options by funds: $19K | Put options by funds: $496K

Holders
134
Holders Change
+1
Holders Change %
+0.75%
% of All Funds
2.94%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
47
Reduced
50
Closed
15
Calls
$19K
Puts
$496K
Net Calls
-$477K
Net Calls Change
+$19K

Top Buyers

Rank Fund Capital Flow
1
VOYA Investment Management
VOYA Investment Management
Georgia
+$12.2M
2
Marshall Wace
Marshall Wace
United Kingdom
+$8.61M
3
Invesco
Invesco
Georgia
+$8.23M
4
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$5.99M
5
SAM
Silvercrest Asset Management
New York
+$4.81M

Top Sellers

Rank Fund Capital Flow
1
N
Nuveen
North Carolina
-$5.65M
2
ACM
Argent Capital Management
Missouri
-$3.97M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.43M
4
Allianz Asset Management
Allianz Asset Management
Germany
-$1.61M
5
Canada Life
Canada Life
Manitoba, Canada
-$979K
Name Holding Trade Value Shares
Change 		Change in
Stake
KFS
126
Kelly Financial Services
Massachusetts
$2.98K – – –
LWA
127
Lowe Wealth Advisors
Maryland
$2K – – –
PFBT
128
Parkside Financial Bank & Trust
Missouri
$1K +$354 +17 +77%
GWS
129
Glassman Wealth Services
Virginia
$1K +$791 +38 +317%
Fidelity Investments
130
Fidelity Investments
Massachusetts
$1K +$1.02K +49 New
GT
131
Glenmede Trust
Pennsylvania
$10 -$208 -10 -2%
ACM
132
Argent Capital Management
Missouri
– -$3.97M -188,140 Closed
Point72 Asset Management
133
Point72 Asset Management
Connecticut
– -$3.43M -162,286 Closed
Canada Life
134
Canada Life
Manitoba, Canada
– -$979K -46,463 Closed
RJA
135
Raymond James & Associates
Florida
– -$807K -38,231 Closed
HIM
136
Hillsdale Investment Management
Ontario, Canada
– -$714K -33,800 Closed
Two Sigma Investments
137
Two Sigma Investments
New York
– -$674K -31,917 Closed
AWM
138
AE Wealth Management
Kansas
– -$406K -19,240 Closed
SS
139
Simplicity Solutions
Minnesota
– -$394K -18,659 Closed
SSA
140
Schonfeld Strategic Advisors
New York
– -$358K -17,000 Closed
USAA
141
United Services Automobile Association
Texas
– -$321K -15,207 Closed
LPL Financial
142
LPL Financial
California
– -$312K -14,773 Closed
LCM
143
Laurion Capital Management
New York
– -$283K -13,392 Closed
PP
144
Paloma Partners
Connecticut
– -$248K -11,758 Closed
MFG
145
Magnus Financial Group
New York
– -$204K -9,664 Closed
QCG
146
Quadrant Capital Group
Ohio
– -$54K -2,636 Closed
FGAM
147
Financial Gravity Asset Management
Texas
– -$312 -15 -42%
PHK
148
Point72 Hong Kong
Hong Kong
– +$375 +18 New
2 3 4 5
6

AMPH Hedge Fund Activity: Q3 2019 in Review

134 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q3 2019, worth a combined $478M — up 1.4% from $471M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new AMPH positions and 15 closed out — a net gain of 2 holders — while 47 added to existing stakes and 50 trimmed.

The largest buyer was VOYA Investment Management, adding an estimated $12.2M. The largest seller was Nuveen, cutting an estimated $5.65M.

  • 134 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q3 2019, up from 133 in Q2 2019.
  • Funds reported $478M of Amphastar Pharmaceuticals stock for Q3 2019, up 1.4% quarter-over-quarter.
  • 17 funds opened new Amphastar Pharmaceuticals positions in Q3 2019 and 15 closed out, a net change of +2 holders.
  • The largest Amphastar Pharmaceuticals buyer in Q3 2019 was VOYA Investment Management, an estimated $12.2M added.
  • The largest Amphastar Pharmaceuticals seller in Q3 2019 was Nuveen, an estimated $5.65M sold.

Based on aggregated 13F filings for Q3 2019.